Strategic Partnerships Qnostics has a history of collaboration with industry players (notably Randox Laboratories) to expand reach of its molecular control products. This suggests sales opportunities through channel partnerships, co-marketing agreements, and distributor-friendly packaging that leverages existing networks in IVD, molecular diagnostics, and CRO spaces.

Targeted Markets Primary focus on infectious disease molecular controls indicates strong demand in clinical diagnostics, research labs, and pharmaceutical QA/QC. Opportunities exist to upsell regulatory-compliant controls, validated controls for assay development, and customizable controls tailored to specific panels or platforms.

Geographic Reach With manufacturing in the UK and commercial offices in the UK and US, Qnostics already serves international distribution partners. Growth potential lies in expanding direct sales or exclusive distribution in key regions, leveraging current cross-border capabilities.

Service Expansion Beyond products, Qnostics offers end-to-end support across assay life cycle. There is potential to monetize expanded services such as bespoke material development, regulatory alignment support, and on-market post-launch testing services for partner laboratories.

Financial Position Annual revenue in the $1–10 million range with a lean employee base suggests an agile organization capable of scalable partnerships. Target mid-market organizations and CROs seeking reliable, customizable molecular controls with favorable pricing and flexible terms.